Intraductal Meibomian Gland Probing (MGP) — Clinical Evidence at a Glance

Intraductal Meibomian Gland Probing (MGP) — Clinical Evidence at a Glance

Synthesized from seven works by Maskin and colleagues (2018–2024)

Disease Mechanism — Why Probe?

  • MGD is often a fixed fibrotic obstruction, not just thickened meibum — palliative heat/pressure cannot address it alone and there’s risk of further disease progression.
  • Maskin & Alluri, Cornea 2019: in 11,776 glands across 404 lids in 108 patients, 84% showed mechanical resistance and ~67% showed fixed, firm, focal, unyielding resistance (FFFUR).
  • Fixed obstruction is independent of expressibility: lids with >90% expressible glands had statistically the same FFFUR rate as lids with 0% — an expressible gland can harbor an occult fixed stricture.

Procedural Validation & Safety

  • Maskin & Alluri, BJO 2020 (real-time IR meibography, 996 probed orifices): 99.9% successful entry, probe location confirmed in 91.8%, no false passages. Confirms intraductal probe placement and demonstrates that the probe’s flexibility allows it to remain within the duct, even in tortuous glands. Across all 10 independent studies in the 2023 review: no adverse events reported.
  • 2024 IVCM: probe track remains within the ductal epithelium while also exfoliating senescent cells; no fibroblast activation, no scar tissue, no duct wall perforation.

Clinical Efficacy — Convergent Across Independent Investigators

  • Warren & Maskin (Clin Ophthalmol 2023): ten independent peer-reviewed studies across US, China, Turkey, India, Cuba, Japan, Mexico, Russia — every one demonstrated improved symptoms and/or signs after MGP, despite heterogeneous protocols.
  • Four RCTs, head-to-head: MGP beat sham probing (Kheirkhah), IPL (Huang — 20% vs. 35.7% retreatment), topical steroid alone (Ma & Lu), and conventional therapy (Incekalan, faster onset).
  • Maskin series (2019 procedure paper): lid tenderness resolved in 86% / 82% / 58% of lids at 1 wk / 3–6 mo / 1 yr; non-tenderness VAS symptoms (burning, photophobia) ↓ 35% / 66% / 80% immediately 1 mo. / 3-6 mo.; expressible glands per lid 2.8 → 14.4 (412% increase, p<0.0001).,
  • Representative magnitudes from reviewed studies: TBUT 5.33 → 9.87 s; OSDI 26 → 13.5 at 6 mo (both p=0.0001).

Gland Regeneration, Cellular and other (2018 IRM and 2024 IVCM Study)

  • 36 identical gland pairs in 16 probed MGD patients vs. 13 pairs in 4 unprobed MGD controls.
  • Post-MGP: duct wall epithelial cell layers ↑32.2%; duct wall thickness ↑25.4% distal / 32.0% proximal; lumen area ↑77.7% distal / 81.3% proximal (all p<0.001).
  • Duct wall thickens while lumen dilates — indicates regenerative growth, not fibrotic constriction. Effect maximizes at 3 months and remains durable to 13 months; unprobed controls show no significant change.
  • Structural changes seen distally continue more proximally – suggests regeneration extends the length of the gland
  • Provides cytological explanation for findings of 2019 procedure paper where VAS symptoms excluding lid tenderness (burning, photophobia) achieved maximum improvement at 3 months, aligning with maximum duct wall thickness and lumen dilation
  • Maskin & Testa, BJO 2018 (IR meibography, 50 upper lids in 28 MGD patients): 41.2% of lids showed signs of gland growth at ≤12 mo follow-up; mean individual glandular area (MIGA) ↑4.87% collectively (p=0.0145), with individual lids gaining up to 21.13% (p<0.0001) —tissue regrowth visible on meibography, complementing the IVCM cellular findings above.

Defensible Clinical Conclusions

  • Evidence supports MGP as an effective treatment for MGD, especially when fixed intraductal obstruction or lid tenderness is present.
  • MGP restores or confirms ductal patency and is associated with improved symptoms, tear film metrics, meibum expressibility, and lid margin signs.
  • Emerging imaging evidence suggests MGP may stimulate ductal epithelial proliferation and remodeling.
  • Persuasive force is convergence: a quantified lesion + imaged engagement + consistent clinical benefit + cellular-level regeneration.

Caveats: Foundational work is largely retrospective/observational; independent RCTs are small (~40–50 patients). Inventor/author overlap and patent interest disclosed. None of these caveats reverse the direction of the evidence.

References:

  1. Maskin SL, Toland C. Meibomian Gland Probing Stimulates a Proliferative Epithelial Response Resulting in Duct Regeneration. Clin Ophthalmol. 2024;18:631–645.
  2. Warren NA, Maskin SL. Review of Literature on Intraductal Meibomian Gland Probing with Insights from the Inventor and Developer: Fundamental Concepts and Misconceptions. Clin Ophthalmol. 2023;17:497–514.
  3. Maskin SL, Warren NA. Your Dry Eye Mystery Solved: Reversing Meibomian Gland Dysfunction, Restoring Hope. Yale University Press; 2022.
  4. Maskin SL, Alluri S. Meibography guided intraductal meibomian gland probing using real-time infrared video feed. Br J Ophthalmol. 2020;104(12):1676–1682.
  5. Maskin SL, Alluri S. Intraductal meibomian gland probing: background, patient selection, procedure, and perspectives. Clin Ophthalmol. 2019;13:1203–1223.
  6. Maskin SL, Alluri S. Expressible meibomian glands have occult fixed obstructions: findings from meibomian gland probing to restore intraductal integrity. Cornea. 2019;38(7):880–887.
  7. Maskin SL, Testa W. Growth of meibomian gland tissue after intraductal meibomian gland probing in patients with obstructive meibomian gland dysfunction. Br J Ophthalmol 2018;102:59–68.